>IMOJOGFE_00001 hypothetical protein
MENTINESGKKKRFKLKMPGAFMILFILTVVAVIATWVIPAGAYSKLSYEPSSQELKIVN
PHNQVKKVPGTQQELDKMGVKIKIEQFKSGAINKPVSIPNTYERLKQHPAGPEQITSSMV
EGTIEAVDIMVFILVLGGLIGVVQASGSFESGLLALTKKTKGHEFMLIVFVSILMIIGGT
LCGIEEEAVAFYPILVPIFIALGYDSIVSVGAIFLASSVGSTFSTINPFSVVIASNAAGT
TFTDGLYWRIGACIVGAIFVISYLYWYCKKIKKDPKASYSYEDKDAFEQQWSVLKDDDSA
HFTLRKKIILTLFVLPFPIMVWGVMTQGWWFPVMASAFLIFAIIIMFIAGTGKSGLGEKG
TVDAFVNGASSLVGVSLIIGLARGINLVLNEGMISDTILHFSSSLVQHMSGPLFIIVLLF
IFFCLGFIVPSSSGLAVLSMPIFAPLADTVGIPRFVIVTTYQFGQYAMLFLAPTGLVMAT
LQMLNMRYSHWFRFVWPVVAFVLIFGGGVLITQVLIYS
>IMOJOGFE_00002 Carbamate kinase 1
MMAKIVVALGGNALGKSPQEQLELVKNTAKSLVGLITKGHEIVISHGNGPQVGSINLGLN
YAAEHNQGPAFPFAECGAMSQAYIGYQLQESLQNELHSIGMDKQVVTLVTQVEVNENDPA
FNNPSKPIGLFYNKEEAEQIQKEKGFIFVEDAGRGYRRVVPSPQPISIIELESIKTLIKN
DTLVIAAGGGGIPVIREQHDGFKGIDAVIDKDKTSALLGANIQCDQLIILTAIDYVYINF
NTENQQPLETTNVDELKRYIDENQFAKGSMLPKIEAAISFIENNPKGSVLITSLNELDAA
LEGKVGTVIKK
>IMOJOGFE_00003 Ornithine carbamoyltransferase
MKNLRNRSFLTLLDFSRQEVEFLLTLSEDLKRAKYIGTEKPMLKNKNIALLFEKDSTRTR
CAFEVAAHDQGANVTYLGPTGSQMGKKETTKDTARVLGGMYDGIEYRGFSQRTVETLAEY
SGVPVWNGLTDEDHPTQVLADFLTAKEVLKKDYADINFTYVGDGRNNVANALMQGAAIMG
MNFHLVCPKELNPTDELLNRCKNIAAENGGNILITDDIDQGVKGSDVIYTDVWVSMGEPD
EVWKERLELLKPYQVNKEMMDKTGNPNVIFEHCLPSFHNADTKIGQQIFEKYGIREMEVT
DEVFESKASVVFQEAENRMHTIKAVMVATLGEF
>IMOJOGFE_00004 Superantigen-like protein 13
MKKNIMNKLVLSTALLLLGTTSTQLPKTPISFSSEAKAYNISENETNINELIKYYTQPHF
SLSGKWLWQKPNGSIHATLQTWVWYSHIQVFGAESWGNINQLRDKYVDIFGTKDEDTVEG
YWTYDETFTGGVTPAATSSDKSYKLFLKYSDKQQTIIGGLEFYKGNKPVLTLKELDFRIR
QTLINNKKLYNGEFNKGQIKITGGGNNYTIDLSKKLKLTDTNRYVKNPRHAEIEVILEKS
N
>IMOJOGFE_00005 Superantigen-like protein 13
MKKNITKKIILSSALLLLGAVSTQLPNTPISSKSEAKAYYINQEETNVSELIKYYTQQHL
TFSNKWLWQKDNGTIHATLLQISWYSHIQVFGPESWGNINQLRDKYVDIFGIKDQETIDS
YALSQETFTGGVTPAAKPNDKHYKLNVTYKDKDETFIGGYPFYTGNKPVLTLKEVDFRIR
QTLIKNKKLYQDKYNKGQLTITGDDNNYTIDLSKRLPSTDANKYVKNPQNAKIEVTLEKS
N
